Is ADPT stock a buy?

Adaptive Biotechnologies has received a consensus rating of Buy. The company’s average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

How many employees does Adaptive Biotechnologies have?

Adaptive Biotechnologies has 453 employees.

Is Adaptive Biotechnologies a good investment?

Valuation metrics show that Adaptive Biotechnologies Corporation may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ADPT, demonstrate its potential to underperform the market.

How many patents does Adaptive Biotechnologies have?

70 patents
Adaptive Biotechnologies Patents Adaptive Biotechnologies has filed 70 patents.

When did ADPT go public?

The gross proceeds from the offering were approximately $345.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The shares commenced trading on The Nasdaq Global Select Market on June 27, 2019, under the ticker symbol “ADPT”. Goldman Sachs & Co.

Is adaptive a public company?

Adaptive is the first Seattle-area company to go public since tax automation software maker Avalara had its IPO in June 2018. Smartsheet, DocuSign, and nLight were the other Washington state companies that had an IPO last year.

When did Adaptive Biotechnologies go public?

2019
The firm went public in 2019, raising about $300 million in its IPO. Adaptive expects the offering to close on or around July 20. In Thursday morning trade on the Nasdaq, shares of Adaptive were down around 8 percent at $40.25.

Is adaptive biotech public?

SEATTLE , July 15, 2020 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of an underwritten public offering …

Who owns adaptadaptive Biotechnologies’stock?

Adaptive Biotechnologies’ stock is owned by many different institutional and retail investors.

When is adaptive Biotechnologies’next quarterly earnings announcement?

Adaptive Biotechnologies is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022. View our earnings forecast for Adaptive Biotechnologies. How were Adaptive Biotechnologies’ earnings last quarter? Adaptive Biotechnologies Co. (NASDAQ:ADPT) posted its quarterly earnings results on Tuesday, November, 2nd.

Who underwrote adaptive Biotechnologies’IPO?

Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. What is Adaptive Biotechnologies’ stock symbol? Adaptive Biotechnologies trades on the NASDAQ under the ticker symbol “ADPT.” Who are Adaptive Biotechnologies’ major shareholders?

Is adaptive Biotechnologies (ATN) stock a good buy?

Adaptive Biotechnologies has received a consensus rating of Buy. The company’s average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings. According to analysts’ consensus price target of $60.33, Adaptive Biotechnologies has a forecasted upside of 127.6% from its current price of $26.51.